

Back to [Journals](#) » [The Application of Clinical Genetics](#) » Volume 15

8 | 1 | 5 | 1 | 3

**Papers Published**
[Submit New Manuscript](#)
[Login to view existing manuscript status](#)
[Signup for Journal alerts](#)
**About Dove Press**

Open access peer-reviewed scientific and medical journals.

[Learn more](#)
**Open Access**

Dove Medical Press is a member of the OAI.

[Learn more](#)
**Reprints**

Bulk reprints for the pharmaceutical industry.

[Learn more](#)
**Favored Authors**

We offer real benefits to our authors, including fast-track processing of papers.

[Learn more](#)
**Promotional Article Monitoring**

Register your specific details and specific drugs of interest and we will match the information you provide to articles from our extensive database and email PDF copies to you promptly.

[Learn more](#)

ESCI (EMERGING SOURCES CITATION INDEX) | SJR OA (SJR SCIMAGO JOURNAL &amp; COUNTRY RANK) | CITESCORE ()

**The Application of Clinical Genetics**

ISSN: 1178-704X


[About Journal](#) | [Journal Metrics](#) | [Editors](#) | [Peer Reviewers](#) | [Articles](#)

<a href="#">View all</a> (273)	<a href="#">Volume 16, 2023</a> (4)	<b>Volume 15, 2022</b> (16)
<a href="#">Volume 14, 2021</a> (37)	<a href="#">Volume 13, 2020</a> (23)	<a href="#">Volume 12, 2019</a> (30)
<a href="#">Volume 11, 2018</a> (23)	<a href="#">Volume 10, 2017</a> (12)	<a href="#">Volume 9, 2016</a> (22)
<a href="#">Volume 8, 2015</a> (24)	<a href="#">Volume 7, 2014</a> (23)	<a href="#">Volume 6, 2013</a> (12)
<a href="#">Volume 5, 2012</a> (13)	<a href="#">Volume 4, 2011</a> (14)	<a href="#">Volume 3, 2010</a> (15)
<a href="#">Volume 2, 2009</a> (2)	<a href="#">Volume 1, 2008</a> (3)	

Search Articles

Search

**Archive: Volume 15, 2022**

ORIGINAL RESEARCH

**RASopathy Cohort of Patients Enrolled in a Brazilian Reference Center for Rare Diseases: A Novel Familial LZTR1 Variant and Recurrent Mutations**

Chaves Rabelo N, Gomes ME, de Oliveira Moraes I, Cantagalli Pfisterer J, Loss de Moraes G, Antunes D, Caffarena ER, Llerena Jr J, Gonzalez S

[The Application of Clinical Genetics 2022](#), 15:153-170

Published Date: **21 October 2022**

ORIGINAL RESEARCH

**Prenatal Sonographic Features of Rare Chromosome 13 Aberrations**

Moczulska H, Pietrusinski M, Serafin M, Skoczylas B, Sieroszewski P, Borowiec M

[The Application of Clinical Genetics 2022](#), 15:145-151

Published Date: **3 October 2022**

ORIGINAL RESEARCH

**Three-Decade Successive Establishment of Care for Women/Girls from Families with Haemophilia**

Chuansumrit A, Sasanakul W, Sirachainan N, Santiwatana S, Kadegasem P, Wongwerawattanakoon P, Tungbubpha N, Chantaraamporn J

[The Application of Clinical Genetics 2022](#), 15:133-143

Published Date: **1 October 2022**

CASE REPORT

**Case Report of a Juvenile Patient with Autism Spectrum Disorder with a Novel Combination of Copy Number Variants in ADGRL3 (LPHN3) and Two Pseudogenes**

Maurer MH, Kohler A, Hudemann M, Jüngling J, Biskup S, Menzel M

[The Application of Clinical Genetics 2022](#), 15:125-131

Published Date: **2 September 2022**

Social Media

Need help?

REVIEW 

### **ABCD1 Gene Mutations: Mechanisms and Management of Adrenomyeloneuropathy**

Volmrich AM, Cuénant LM, Forghani I, Hsieh SL, Shapiro LT

[The Application of Clinical Genetics 2022](#), 15:111-123

Published Date: **12 August 2022**

ORIGINAL RESEARCH

### **Long Non-Coding RNAs ASB16-AS1 and AFAP1-AS1: Diagnostic, Prognostic Impact and Survival Analysis in Colorectal Cancer**

Elabd NS, Soliman SE, Elhamouly MS, Gohar SF, Elgamel A, Alabassy MM, Soliman HA, Gadallah AA, Elbahr OD, Soliman G, Saleh AA

[The Application of Clinical Genetics 2022](#), 15:97-109

Published Date: **1 August 2022**

ORIGINAL RESEARCH 

### **Utility of Measuring Fetal Cavum Septum Pellucidum (CSP) Width During Routine Obstetrical Ultrasound for Improving Diagnosis of 22q11.2 Deletion Syndrome: A Case-Control Study**

Pylypjuk CL, Memon SF, Chodirker BN

[The Application of Clinical Genetics 2022](#), 15:87-95

Published Date: **26 July 2022**

ORIGINAL RESEARCH

### **Deregulation of CircANXA2, Circ0075001, and CircFBXW7 Gene Expressions and Their Predictive Value in Egyptian Acute Myeloid Leukemia Patients**

Tayel SI, Soliman SE, Ahmedy IA, Abdelhafez M, Elkholy AM, Hegazy A, Muharram NM

[The Application of Clinical Genetics 2022](#), 15:69-85

Published Date: **16 July 2022**

CASE REPORT

### **A Novel POGZ Variant in a Patient with Intellectual Disability and Obesity**

Giraldo-Ocampo S, Pacheco-Orozco RA, Pachajoa H

[The Application of Clinical Genetics 2022](#), 15:63-68

Published Date: **6 July 2022**

ORIGINAL RESEARCH

### **Evaluating the Association Between Genetic Polymorphisms Related to Homocysteine Metabolism and Unexplained Recurrent Pregnancy Loss in Women**

Nguyen Ngoc N, Tran Ngoc Thao M, Trieu Tien S, Vu Tung S, Le H, Ho Sy H, Nguyen Thanh T, Trinh The S

[The Application of Clinical Genetics 2022](#), 15:55-62

Published Date: **7 June 2022**

ORIGINAL RESEARCH 

### **Prominent Mutation of Intron 22 Inversion in Sporadic Hemophilia: Is It Worth the Antenatal Screening?**

Sasanakul W, Chuansumrit A, Sirachainan N, Kadegasem P

[The Application of Clinical Genetics 2022](#), 15:49-54

Published Date: **19 May 2022**

ORIGINAL RESEARCH 

### **Molecular Genetic Screening of Neonatal Intensive Care Units: Hyperbilirubinemia as an Example**

Yang Y, Wang Y, Zhou L, Long W, Yu B, Wang H

[The Application of Clinical Genetics 2022](#), 15:39-48

Published Date: **18 May 2022**

CASE SERIES 

### **Clinical Importance of aCGH in Genetic Counselling of Children with Psychomotor Retardation**

Pasińska M, Łazarczyk E, Repczyńska A, Sobczyńska-Tomaszewska A, Zimowski J, Runge A, Haus O

[The Application of Clinical Genetics 2022](#), 15:27-38

Published Date: **14 May 2022**

ORIGINAL RESEARCH 

### **CTLA-4 CT-60 A/G and CTLA-4 1822 C/T Gene Polymorphisms in Indonesians with Type 1 Diabetes Mellitus**

Rochmah N, Faizi M, Nova S, Setyoningrum RA, Basuki S, Endaryanto A

[The Application of Clinical Genetics 2022](#), 15:19-25

Published Date: **29 April 2022**

ORIGINAL RESEARCH 

### **HLA-DQA1 and HLA-DQB1 Gene Polymorphism in Indonesian Children with Type I Diabetes Mellitus**

Soetjipto, Rochmah N, Faizi M, Hisbiyah Y, Endaryanto A

[The Application of Clinical Genetics 2022](#), 15:11-17

Published Date: **12 January 2022**

CASE REPORT 

### **Novel Compound Heterozygous Variants in the CDC6 Gene in a Russian Patient with Meier-Gorlin Syndrome**

Zabnenkova V, Shchagina O, Makienko O, Matyushchenko G, Ryzhkova O

[The Application of Clinical Genetics 2022](#), 15:1-10

Published Date: **6 January 2022**

[Contact Us](#) • [Privacy Policy](#) • [Associations & Partners](#) • [Testimonials](#) • [Terms & Conditions](#) • [Recommend this site](#) • [Top](#)

© Copyright 2023 • Dove Press Ltd • software development by maffey.com • Web Design by Adhesion

The opinions expressed in all articles published here are those of the specific author(s), and do not necessarily reflect the views of Dove Medical Press Ltd or any of its employees.

Dove Medical Press is part of Taylor & Francis Group, the Academic Publishing Division of Informa PLC

Copyright 2017 Informa PLC. All rights reserved. This site is owned and operated by Informa PLC ("Informa") whose registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36

[Submit New Manuscript](#)
[Login to view existing manuscript status](#)
[Signup for Journal alerts](#)

### About Dove Press

Open access peer-reviewed scientific and medical journals.

[Learn more](#)

### Open Access



Dove Medical Press is a member of the OAI.

[Learn more](#)

### Reprints

Bulk reprints for the pharmaceutical industry.

[Learn more](#)

### Favored Authors

We offer real benefits to our authors, including fast-track processing of papers.

[Learn more](#)

### Promotional Article Monitoring

Register your specific details and specific drugs of interest and we will match the information you provide to articles from our extensive database and email PDF copies to you promptly.

[Learn more](#)

### Social Media

[Back to Journals](#)

ESCI (EMERGING SOURCES CITATION INDEX) SJR OA (SJR SCIMAGO JOURNAL & COUNTRY RANK) CITESCORE ()

## The Application of Clinical Genetics

ISSN: 1178-704X


[About Journal](#) | [Journal Metrics](#) | [Editors](#) | [Peer Reviewers](#) | [Articles](#)
[Article Publishing Charges](#) | [Aims and Scope](#) | [Call For Papers](#)

### Prof. Dr. Martin H Maurer

EDITOR IN CHIEF

Professor Dr. med. Martin H Maurer is Associate Professor of Physiology at the University of Heidelberg, Germany. He also holds a position as physician at the Marienberg Hospital for Child and Adolescent Psychiatry in Gammertingen, Germany. He is board licensed as specialist for physiology at the Board of Physicians of the State of Baden-Württemberg, Germany.

Education and Appointments: He earned his degree as M.D. at the University of Heidelberg in 1999 and held positions as a post-doctoral fellow at the Department of Physiology and Pathophysiology, University of Heidelberg, Germany, from 2000 to 2005, and the Department of Psychiatry and Behavioral Sciences at the Johns Hopkins University, Baltimore, Maryland, USA in 2003. Professor Maurer holds an appointment as faculty at the University of Heidelberg, Germany since 2005, first as assistant professor ("Priv.-Doz."), since 2007 as associate professor ("apl. Prof.").

Basic Research: Professor Maurer introduced the high-throughput technology of proteomics into neural stem cell research with the aim of identifying protein sets which define stem cell populations, and factors which are responsible for neural development of stem cells in the brain. Moreover, his research focused on the functions of hematopoietic growth factors like vascular endothelial growth factor (VEGF), erythropoietin (EPO) and granulocyte colony stimulating factor (G-CSF) on neuronal precursor cells.

Clinical Research: With regard to his clinical research interests, his current focus is the application of neuropharmacological agents in neurodevelopmental disorders. He also worked on genetic testing for neurodegenerative disorders, such as fragile X syndrome, and spinocerebellar ataxias.

He is member of the honorary editorial board of the Application of Clinical Genetics since its inauguration in 2008, and was appointed Editor-in-Chief in 2012.



Prof. Dr. Maurer



## Editorial Board

11 Members

### Professor Al-Mulla KUWAIT



Fahd Al-Mulla, Professor in Genomic medicine and molecular pathology, Department of Pathology, Kuwait University, Kuwait, and the Chief Scientific Office at the Dasman Diabtetes Institute, Kuwait.

### Prof. Dr. Ali-Osman UNITED STATES

Francis Ali-Osman, Professor of Neurosurgery, Duke University School of Medicine, Durham, North Carolina, USA

### Professor Comai UNITED STATES

Lucio Comai, Professor, Department of Molecular Microbiology and Immunology, Keck School of Medicine USC, CA, USA

### Professor Deng UNITED STATES



Hong-Wen Deng, Ph. D. Professor, Chief, Section of Biomedical Informatics and Genomics. Director, Tulane Center of Biomedical Informatics and Genomics Deming Department of Medicine, School of Medicine, Tulane University, New Orleans, USA.

### Professor Hu UNITED STATES



Jennifer J. Hu, Professor, Public Health Sciences, Miller School of Medicine, University of Miami, FL, USA

### Professor Lupski UNITED STATES

James R. Lupski, Professor, Department of Molecular and Human Genetics, Baylor College of Medicine, TX, USA

### Prof. Dr. Maurer GERMANY



Martin H. Maurer, Professor, Department of Physiology and Pathophysiology, University of Heidelberg, Germany

### Dr Parine SAUDI ARABIA



Dr. Narasimha Reddy Parine, Assistant Professor, Genome Research Chair, Department of Biochemistry, College of Science, King Saud University, Riyadh, Saudi Arabia.


### Dr Saudino UNITED STATES

Kimberly J. Saudino, Psychology Department, Boston University and Director, Boston University Twin Project, MA, USA

### Dr Tanzi UNITED STATES

Rudolph Tanzi, Professor, Department of Neurology, Harvard Medical School, Massachusetts General Hospital, MA, USA.

### Professor Urzúa CHILE



Blanca Urzúa Orellana, (PhD), Associate Professor, Academic at the Institute for Research in Dental Sciences, Biochemistry Area, Laboratory of Biochemistry and Oral Biology, Faculty of Dentistry, University of Chile.

[Contact Us](#) • [Privacy Policy](#) • [Associations & Partners](#) • [Testimonials](#) • [Terms & Conditions](#) • [Recommend this site](#) • [Top](#)

© **Copyright 2023** • **Dove Press Ltd** • software development by maffey.com • Web Design by Adhesion

The opinions expressed in all articles published here are those of the specific author(s), and do not necessarily reflect the views of Dove Medical Press Ltd or any of its employees.

Dove Medical Press is part of Taylor & Francis Group, the Academic Publishing Division of Informa PLC

Copyright 2017 Informa PLC. All rights reserved. This site is owned and operated by Informa PLC ( "Informa") whose registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36

# HLA-DQA1 and HLA-DQB1 Gene Polymorphism in Indonesian Children with Type I Diabetes Mellitus

Soetjipto<sup>1,2,\*</sup>  
 Nur Rochmah<sup>2,3,\*</sup>  
 Muhammad Faizi<sup>2,3</sup>  
 Yuni Hisbiyah<sup>2,3</sup>  
 Anang Endaryanto<sup>2,3</sup>

<sup>1</sup>Department of Medical Biochemistry, Faculty of Medicine, Universitas Airlangga, Surabaya, East Java, Indonesia;

<sup>2</sup>Doctoral Program of Medical Science, Faculty of Medicine, Universitas Airlangga, Surabaya, East Java, Indonesia;

<sup>3</sup>Faculty of Medicine, Department of Child Health, Dr. Soetomo General Hospital, Universitas Airlangga, Surabaya, East Java, Indonesia

\*These authors contributed equally to this work

**Background:** More than 40 genes influence the progression of type 1 diabetes mellitus (T1DM), including human leukocyte antigen (HLA) alleles. Different HLA genotype patterns result in diverse rates of T1DM development. HLA class II DR, DQ, and DP vary among different populations and ethnicities. Data on HLA polymorphism in T1DM in Indonesia are lacking. Therefore, this study was designed to evaluate the gene polymorphism of HLA-DQA1 and HLA-DQB1 in Indonesian children with T1DM.

**Patients and Methods:** In this study, 31 patients with T1DM and 31 controls were enrolled from April 2020 to April 2021. This study was conducted at Dr. Soetomo Hospital, Indonesia. We evaluated the gene polymorphism of HLA-DQA1 and HLA-DQB1 using polymerase chain reaction–restriction fragment length polymorphism. The primers used were as follows: for HLA-DQA1, DQAS34: 5'-GGTGTAACCTGTACCAG-3' (forward) and DQAA261: 5'-ATTGGTAGCAGCGGTAGA-3' (reverse); for HLA-DQB1, DQBS43: 5'-TGCTACTTCACCAA(C/T)GGG-3' (forward) and DQBA249: 5'-GTAGTTGTGTCTGCA (C/T)AC-3' (reverse).

**Results:** The most common HLA-DQA1 subtype in the T1DM group was 0101/0102 accounting for 67.6%, and 01/03 and 02/03 were found in the T1DM group only. Meanwhile, the most common HLA-DQB1 subtype in the T1DM group was 0301, accounting for 54.8%. Most subjects in this study were Javanese.

**Conclusion:** HLA-DQA1 0101/0102 and HLA-DQB1 0301 were commonly found in Indonesian children with T1DM.

**Keywords:** T1DM, HLA-DQA1, HLA-DQB1, gene polymorphism

## Introduction

Type 1 diabetes mellitus (T1DM) is one of the most frequent chronic illnesses among children. The prevalence of T1DM is 5%–10% of all diabetes mellitus cases. Approximately 30 million people live with T1DM worldwide, with an estimated three-fold increase in prevalence by 2040.<sup>1</sup> The prevalence of T1DM in Asia is surprisingly low, with 0.4–1.1 cases per 100,000 individuals per year.<sup>2</sup> Studies have shown that T1DM has genetic susceptibility associated with gene polymorphisms or mutations. More than 40 genes influence the progression of T1DM, including human leukocyte antigen (HLA). Different HLA genotype patterns result in diverse rates of T1DM development. HLA class II DR, DQ, and DP vary among different populations and ethnicities.<sup>3</sup> Associations between HLA genes and T1DM were first reported among Caucasians with class I molecules B8 or B15.1. For example,

Correspondence: Soetjipto  
 Doctoral Program of Medical Science,  
 Faculty of Medicine, Universitas Airlangga,  
 Mayjend Prof. Dr. Moestopo No. 6-8,  
 Surabaya, East Java. 60286, Indonesia  
 Email Soetjipto1950@gmail.com

the high-risk HLA haplotypes in Caucasian populations, DRB1\*03:01-DQB1\*02:01 and DRB1\*04:01-DQB1\*03:02, were found to be low in incidence in Japan and Southeast Asia.<sup>4</sup> A study conducted in Southeast Asia has proven this finding, where the most prevalent HLA types were DQA1\*0501 (50.7% vs 20.4%; RR = 3.97; Pc < 0.01), DQB1\*0201 (48% vs 19.1%; RR = 3.86; Pc < 0.05), and DRB1\*0301 (38.7 vs 6.8%; RR = 8.36; 95% Pc < 0.05).<sup>5</sup>

The pathophysiology of T1DM revolves around B cell destruction. It is thought to be related to autoreactive CD4+ helper and CD8+ cytotoxic T cells in response to at least four major antigens (ie, insulin derivatives, glutamic acid decarboxylase-65 [GAD-65], tyrosine phosphatase, and zinc transporter-8 [ZnT8]) present in pancreatic B cells. Antibodies found against these elements are good markers for T1DM.<sup>6–8</sup> In India, a study on the prevalence of GAD antibody (GADA), ZnT8, and HLA and their diagnostic values in T1DM has found a low sensitivity of GADA and ZnT8. They concluded that for diagnosing T1DM, GADA is the most superior autoantibody. Its sensitivity is low; hence, it should be combined with HLA.<sup>9</sup> This finding is similar to those found in Asian literature and contradicts those found in some Western studies.<sup>10–12</sup>

Studies on this particular area in Asia remain limited.<sup>9</sup> Therefore, this study was designed to evaluate gene polymorphisms of HLA-DQA1 and HLA-DQB1 in Indonesian children with T1DM.

## Patients and Methods

### Study Design

This was a case–control study comparing HLA-DQA1 and HLA-DQB1 gene polymorphisms between children with T1DM and those without T1DM (control).

### Subjects

In this study, 31 children with T1DM who were present for follow-up at the pediatric endocrine clinic at Dr. Soetomo General Hospital Surabaya were enrolled. For comparison, we included 31 healthy children without a history of T1DM who also attended the pediatric clinic at Dr. Soetomo General Hospital Surabaya as controls. The inclusion criteria for the subjects were as follows:

1. The T1DM group included children diagnosed with T1DM according to the diagnostic criteria from American Diabetes Association (ADA) 2012, as

follows: (1) glucosuria symptoms, ketonuria, and random plasma glucose of more than 200 mg/dL or (2) fasting blood glucose of more than 126 mg/dL with a plasma glucose level of more than 200 mg/dL 2 hours after oral glucose tolerance test (OGTT) or (3) a plasma glucose level of more than 200 mg/dL 2 hours after OGTT or (4) Glycated hemoglobin (HbA1c) of  $\geq 6.5\%$ . Meanwhile, the control group consisted of healthy children without a history of T1DM.

2. Children aged 4–18 years.
3. Children with low C-peptide or at least 1 antibody marker detected.
4. Children whose parents consented to participate in the study.

Patients with T1DM who were admitted to the pediatric intensive care unit with severe disease were excluded. The exclusion criteria for the control group were as follows: (1) ongoing infection, (2) history of other autoimmune diseases, (3) history of allergy, and (4) history of malignancy. Sampling for both the T1DM and control groups was performed using a consecutive sampling method. Ethical approval was obtained by the Ethical Board Committee of Dr. Soetomo Hospital, Indonesia (approval no. 1889/KEPK/III/2020). All participants and their parents provided informed consent, and this study was conducted in accordance with the Declaration of Helsinki.

### DNA Extraction and Genotyping

DNA was obtained from peripheral blood mononuclear cells with a standard method using the QIAmp DNA Mini Kit (Qiagen©). HLA-DQA1 genotyping was performed using polymerase chain reaction (PCR) with forward primer DQAS34: 5'-GGTGTAACCTGTACCAG-3' and reverse primer DQAA261: 5'-ATTGGTAGCAGCGGTAGA-3', resulting in a 228bp DQA1 segment. Meanwhile, for HLA-DQB1, we used forward primer DQBS43: 5'-TGCTACT-TCACCAA(C/T)GGG-3' and reverse primer DQBA249: 5'-GTAGTTGTGTCTGCA(C/T)AC-3', resulting in a 207bp DQB1 segment.<sup>13</sup> For amplification, 35 cycles were performed using the following steps: denaturation at 94°C for 1 min, annealing at 60°C for 2 min, and extension using Taq DNA polymerase at 72°C for 3 min, with the final step after 35 cycles at 72°C for 3–10 min. Amplified DNA was precipitated with ethanol and underwent acrylamide gel 3%.



Polymorphisms were evaluated using PCR–restriction fragment length polymorphism. To evaluate polymorphisms of HLA-DQA1, DdeI and RsaI restriction enzymes were used. Four alleles of DQA1 could be observed after restriction with DdeI: (1) DQA1\*01 (113bp, 74bp, and 41bp fragments); (2) DQA1\*02 (127bp and 98bp fragments); (3) DQA1\*03 (228bp fragment); and (4) DQA1\*04 (154bp and 74bp fragments). The RsaI enzyme was used to further differentiate DQA1\*01 and DQA1\*04 to DQA1\*0101 (188bp), DQA1\*0102 (40bp), DQA1\*0103 (228bp), DQA1\*0401 (185bp), DQA1\*0501 (40bp), and DQA1\*0601 (225bp).<sup>13</sup> The visualization result of PCR-RFLP is shown in Figure 1.

Acyl, HhaI, Sau961, and MspI restriction enzymes were used to evaluate the polymorphism of HLA-DQB1. The Acyl enzyme produced DQB1\*0501 (133bp, 46bp, 26bp, and 2bp) and 0502 (77bp, 56 bp, 48bp, and 26bp). The Sau961 enzyme produced 0503 allele (167bp, 39bp, and 1bp) and 0401 or 0402 (151 bp, 39bp, and 17 bp). The HhaI enzyme produced 0602 or 0603 (104bp, 46bp, 29bp, 26bp, and 2bp), 0604 (133bp, 46bp, 26bp, and 2bp), and 0302 (108bp and 26bp). The MspI restriction enzyme produced the following alleles: (1) DQB1\*0301 (99bp, 72bp, and 36bp fragments); (2) DQB1\*0303 (171bp and 36bp fragments); and (3) DQB1\*0601 (207bp fragment). The HhaI enzyme was used to further differentiate DQB1\*0401 and DQB1\*0402 to DQB1\*0401 (133bp, 72 bp, and 2bp) and DQB1\*0402 (133 bp, 46bp, 26bp, and 2bp), respectively.<sup>13</sup>

## Outcomes

The primary outcome of this study was the subtypes of HLA polymorphism in children with T1DM in Indonesia.

## Statistical Analysis

All statistical analyses were performed using Statistical Package for Social Sciences, version 20.0. Descriptive analysis was conducted to explain the distribution of the subjects' characteristics and HLA polymorphisms. Values are described using mean  $\pm$  standard deviation, and nominal variables are described using numbers (percentages).

## Results

### Clinical Characteristics


The T1DM group consisted of 31 subjects (including 19 girls and 12 boys) with a mean age of  $15 \pm 3.88$  years and body mass index (BMI) of  $19.37 \pm 4.46$  kg/m<sup>2</sup>. The mean age at the onset of T1DM was  $8 \pm 3.72$  years, and the mean T1DM duration was  $7 \pm 4.19$  years. The baseline characteristics are presented in Table 1.

### Allele Frequencies of HLA-DQA1 in the T1DM and Control Groups

In this study, HLA-DQA1 polymorphism was evaluated using two restriction enzymes: DdeI and RsaI. DdeI produced \*01, \*02, \*03, and \*04 subtypes and their combinations. The most common subtype found in the control group was 0601, whereas the most common subtype in the T1DM group was 0101/0102. However, polymorphism between 01/03 and 02/03 was found only in the T1DM group. A complete list of HLA-DQA1 subtypes in the T1DM and control groups is presented in Table 2.

### Allele Frequencies of HLA-DQB1 in the T1DM and Control Groups

HLA-DQB1 polymorphism was evaluated using the Acyl, HhaI, Sau961, and MspI restriction enzymes. The most



**Figure 1** (A) Electrophoresis result from PCR-RFLP of HLA-DQA1 with RsaI restriction enzyme in T1DM groups. (B) Electrophoresis result from PCR-RFLP of HLA-DQA1 with RsaI restriction enzyme in control groups.

**Table 1** Baseline Characteristics of the Subjects in This Study

Characteristics	N = 31			
	T1DM		Control	
	N	%	N	%
Gender				
Boys	19	61.3%	16	51.6%
Girls	12	38.7%	15	48.4%
Ethnicity				
Javanese	27	87.1%	31	100%
Madurese	1	3.2%	0	0
Chinese	1	3.2%	0	0
Malay	2	6.4%	0	0
	<b>N</b>	<b>Mean ± SD</b>	<b>N</b>	<b>Mean ± SD</b>
Age (years)	31	15.05 ± 3.9	31	10.58 ± 2.40
Height (m)	31	1.46 ± 0.19	31	1.29 ± 0.15
Weight (kg)	31	42.62 ± 14.35	31	30.13 ± 11.87
BMI	31	19.37 ± 4.46	31	17.26 ± 3.25

**Table 2** Distribution of HLA-DQA1 Polymorphisms in the T1DM and Control Groups

Polymorphism	T1DM (%)	Control (%)	p
01	5 (16.1)	1 (3.2)	0.09
03	1 (3.2)	2 (6.5)	0.50
04	2 (6.5)	12 (38.7)	0.00
0103	17 (54.8)	18 (58.1)	0.79
0601	19 (61.3)	22 (71.0)	0.42
0101/0102	21 (67.6)	15 (48.4)	0.12
0401/0501	10 (32.3)	2 (6.5)	0.01
01/03	2 (6.5)	0 (0)	0.25
01/04	0 (0)	2 (6.5)	0.25
02/03	2 (6.5)	0 (0)	0.25
03/01	1 (3.2)	2 (6.5)	0.50
03/04	7 (22.6)	4 (12.9)	0.32
01/02/03	2 (6.5)	3 (9.7)	0.50
01/03/01	0 (0)	4 (12.9)	0.06
01/03/04	9 (29.0)	1 (3.2)	0.01

common subtype found in the control group was 0502, whereas the most common subtype in the T1DM group was 0301. The subtypes 0401, 0402, 0501, 0503, 0601, and 0604 were found in both the control and T1DM

groups. A complete list of HLA-DQB1 subtypes in the T1DM and control groups is shown in Table 3.

## Discussion

Most patients with T1DM in this study have HLA-DQA1 0101/0102 (67.6%); however, in the control group, most patients have HLA-DQA1 0601 (71%). Moreover, 01/04 and 01/03/01 polymorphisms were found only in the control group with a ratio of 2:4, whereas 01/03 and 02/03 was found only in the T1DM group.

The most common HLA-DQB1 polymorphism in patients with T1DM in this study was 0301 (54.8%). Furthermore, HLA-DQB1 0302, 0602, and 0603 were found in more patients with T1DM. Meanwhile, HLA-DQB1 0301, 0303, 0403, and 0502 were found in more healthy controls.

Differences in the proportion of alleles and subtypes were observed among different populations. Polymorphism HLA-DR3/DR4 is rarely found in Asia compared with that in European populations. In patients with T1DM, HLA-DQA1 0301/DQB1 0302 (HLA class II) was associated with genetic susceptibility. However, HLA-DQA1\*0102/DQB1\*0602 was protective for T1DM, even in individuals with HLA-DQA1\*0301/DQB1\*0302. Interestingly, a study by Ettinger et al has shown that HLA-DQA1\*0301/DQB1\*0301, HLA-DQA1\*0102/DQB1\*0301, and HLA-DQA1\*0102/DQB1\*0604 were not associated with T1DM although

**Table 3** Distribution HLA-DQB1 Polymorphisms in the T1DM and Control Groups

Polymorphism	T1DM (%)	Control (%)	p
0201	5 (16.1)	5 (16.1)	1.00
0301	17 (54.8)	18 (58.1)	0.79
0302	15 (48.4)	3 (9.7)	0.00
0303	15 (48.4)	17 (54.8)	0.61
0401	31 (100)	31 (100)	–
0402	31 (100)	31 (100)	–
0403	0 (0)	1 (3.2)	0.50
0501	31 (100)	31 (100)	–
0502	10 (32.3)	21 (67.7)	0.01
0503	31 (100)	31 (100)	–
0601	31 (100)	31 (100)	–
0602	15 (48.4)	10 (32.3)	0.19
0603	15 (48.4)	10 (32.3)	0.19
0604	31 (100)	31 (100)	–

they have structural similarity with HLA-DQA1\*0301/DQB1\*0302 and HLA-DQA1\*0102/DQB1\*0604.<sup>14</sup>

A more recent study by Yahaya has shown that HLA-DRB1\*0302–DQA1\*0301 combined with DRB1\*0201–DQA1\*0501 increased the risk of T1DM by 20 folds, whereas the HLA-DQ6 (HLA-DQA1\*0102–DQB1\*0602) haplotype conferred a protective effect.<sup>1</sup>

Studies have reported that the genetic susceptibility of HLA was the most frequently reported.<sup>15–19</sup> This genetic susceptibility varies among ethnicities.<sup>15,18,19</sup> Studies in Iran have reported an association between HLA, gender, specificity, and age at onset. HLA-DRB1\*04:01 and DQB1\*03:02 alleles and DRB1\*04:01–DQB1\*03:02 were the most common haplotypes found in men with T1DM. Meanwhile, DRB1\*03:01, DRB1\*15:01, DQB1\*06:01 alleles, DQB1\*03:01/05:01 genotype, DRB1\*03:01–DQB1\*02:01, and DRB1\*15:01–DQB1\*06:01 were more commonly found in female with T1DM than in males.<sup>20</sup>

DRB1\*03:01–DQB1\*02:01 and DRB1\*04:01–DQB1\*03:02 were lower in Japan and Southeast Asia. The most common HLA polymorphisms in Japan and Korea were DRB1\*04:05–DQB1\*04:01 and DRB1\*09:01–DQB1\*03:03.<sup>21</sup> Meanwhile, in Arabic populations (ie,

Bahrain, Lebanon, and Tunisia), the most common locus was DRB1\*03:01–DQB1\*02:01.<sup>22</sup> A study by Hanscombe has shown that the combination of DRB1\*07:01 and DRB1\*03:03 and DQA1\*03:01–DQB1\*02:01 resulted in the highest risk of T1DM in African–American populations. However, in European populations, HLA-DRB1\*07:01–DQA1\*02:01–DQB1\*02:01 was a protective factor for T1DM.<sup>3</sup>

Hamzeh has reported that 80% of patients with T1DM had HLA-DR3 or HLA-DR4 polymorphisms.<sup>23</sup> In Japan, DR9 haplotype was the most important factor affecting the low incidence of T1DM.<sup>24–26</sup> The profile of HLA in Indonesia is similar to the rest of South East Asian populations. The study reported that polymorphism of HLA-B\*15:02 and HLA-DRB1\*12:02 was frequently found in Javanese, Mollucan, and Nusa Tenggara ethnicities. Indonesia still had different characteristics of HLA compared with other South East Asian countries. Yogyakarta people had high number of DQA1\*0601, DQB1\*03:01, DRB1\*12:02; meanwhile, Western Javanese people had HLA-A\*2407. None of those HLAs are commonly found in other countries.<sup>27</sup>

Most of the patients with T1DM in this study were male, accounting for 61.3% ( $p = 0.45$ ). This result contradicted Katsarou's study that showed that T1DM is more prevalent in females than in males. Another study has reported no significant difference in T1DM prevalence between male and female patients.<sup>28</sup>

The mean age of onset in this study was relevant to the study reported by Katarou that the onset of T1DM increased with age and its peak onset was at the puberty period.<sup>29</sup> Children with T1DM also tended to be underweight at diagnosis. Underweight is a consequence of their catabolic state, resulting in weight loss before the diagnosis.<sup>30</sup> After receiving therapy, the weight of patients with T1DM will increase due to the anabolic effect of insulin therapy.<sup>31</sup>

The limitation of this study was having a small sample size of the participating patients and only conducted in one center. Conducting a multi-center study to obtain more data on Indonesian races is essential.

## Conclusion

The most common HLA-DQA1 subtype in the T1DM group in this study was 0101/0102, whereas the most common HLA-DQB1 subtype is 0602. Further studies should be conducted to find new mutations.

## Acknowledgments

The authors wish to thank the patients, family patients, and endocrine team of Dr. Soetomo Hospital, Surabaya, Indonesia. Soetjipto and Nur Rochmah are co-first authors for this study.

## Disclosure

The authors report no conflicts of interest in this work.

## References

- Yahaya T, Salisu T. Genes predisposing to type 1 diabetes mellitus and pathophysiology: a narrative review. *arXiv preprint*. 2020;29(1):100–109.
- Regnell SE, Lernmark Å. Early prediction of autoimmune (type 1) diabetes. *Diabetologia*. 2017;60(type 1):1370–1381. doi:10.1007/s00125-017-4308-1
- Hanscombe KB, Morris DL, Noble JA, Dilthey AT. Genetic fine mapping of Systemic Lupus Erythematosus MHC associations in Europeans and African Americans. *Human Mol Genetics*. 2018; (August):1–46.
- Jahromi M. Review article Human Leukocyte Antigen (HLA) and islet autoantibodies are tools to characterize type 1 diabetes in Arab countries: emphasis on Kuwait. *Disease Markers*. 2019;2019 (Table 1):9786078.
- Rohana AG, Loh KC, Tin SK, et al. HLA-DQ A1, -DQB1 and -DRB1 gene polymorphism—in Malay type 1 diabetes mellitus patients and their use for riskprediction. *Med J Malaysia*. 2011;66(2):133–137.
- Gabbay MAL, Sato MN, Duarte AJS, Dib SA. Serum titres of anti-glutamic acid decarboxylase- 65 and anti-IA- 2 autoantibodies are associated with different immunoregulatory milieu in newly diagnosed type 1 diabetes patients. *Clin Exp Immunol*. 2011;168:60–67.
- Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. *Lancet*. 2014;383(9911):69–82. doi:10.1016/S0140-6736(13)60591-7
- Thirunavukkarasu R, Asirvatham AJ, Chitra A. SLC30A8 gene rs13266634 C/T polymorphism in children with Type 1 diabetes in Tamil Nadu. *India*. 2019;11(1):55–60.
- Singh S, Singh G, Agrawal NK, Ab Z. Prevalence of autoantibodies and HLA DR, DQ in Type 1 diabetes mellitus. *J Clin Diagn Res*. 2016;10:9–13.
- Chan J, Yeung V, Chow C, et al. Pancreatic p cell function and antibodies to glutamic acid decarboxylase (anti-GAD) in Chinese patients with clinical diagnosis of insulin-dependent diabetes mellitus. *Diabetes Research and Clinical Practice*. 1996;32(1–2):27–34. doi:10.1016/0168-8227(96)01203-x
- Ahmed N, Khan J, Siddiqui T. Frequency of dyslipidaemia in type 2 diabetes mellitus in patients of Hazara division frequency of dyslipidaemia in Type 2 diabetes mellitus in patients of hazara division Nasir Ahmed, Jahangir Khan, Tahir Saeed Siddiqui \*. *J Ayub Med Coll Abbottabad*. 2014;20(2):51–54.
- Wenzlau JM, Liu Y, Yu L, et al. A common nonsynonymous single nucleotide polymorphism in the SLC30A8 gene determines ZnT8 autoantibody specificity in Type 1 diabetes. *Diabetes*. 2008;57(10):2693–2697. doi:10.2337/db08-0522
- Ikegami H, Kawaguchi Y, Yamato E, et al. Analysis by the polymerase chain reaction of histocompatibility leucocyte antigen-DRS-linked susceptibility to insulin-dependent diabetes mellitus. *J Clin Endocrinol Metabol*. 1992;75(November):1381–1385. doi:10.1210/jcem.75.5.1358911
- Ettinger RA, Liu AW, Nepom GT, Kwok WW. Beta 57-Asp plays an essential role in the unique SDSstability of HLA- DQA1\*0102/ DQB1\*0602 alpha beta protein dimer, the class II MHC allele associatedwith protection from insulin-dependent diabetes mellitus. *J Immunol*. 2000;165(6):3232–3238. doi:10.4049/jimmunol.165.6.3232
- Sperling MA, Tamborlane WV, Bettelino T, Weinzimer SA, Philip M. Diabetes mellitus. In: MA Sperling (ed.) *Pediatric Endocrinology*, 4th edn. Philadelphia:Elsevier Saunders; 2014:846–900.
- Dudek NL, Purcell AW. The beta cell immunopeptidome. *Beta Cell*. 2014;95:115–144.
- Van Lummel M, Van Veelen PA, De Ru AH, et al. Discovery of a selective islet peptide presented by the highest-risk HLA-DQ8 trans Molecule. *Diabetes*. 2016;65:732–741.
- Noble JA. Immunogenetics of type 1 diabetes: a comprehensive review. *J Autoimmun*. 2015;64:101–112. doi:10.1016/j.jaut.2015.07.014
- Robertson CC, Rich SS. Genetics of type 1 diabetes. *Curr Opin Genet Dev*. 2018;50(Figure 1):7–16. doi:10.1016/j.gde.2018.01.006
- Sayad A, Ph D, Akbari MT, Ph D, Pajouhi M. Investigation the role of gender on the HLA-DRB1 and -DQB1 association with Type 1 diabetes mellitus in Iranian patients. *Cell Journal*. 2013;15(2):108–115.
- Kawabata Y, Ikegami H, Kawaguchi Y, et al. The contribution of HLA-DR and -DQ haplotypes to susceptibility to Type 1 diabetes. *Diabetes*. 2002;51(2):545–551. doi:10.2337/diabetes.51.2.545
- Stayoussef M, Benmansour J, Al-jenaidi FA, et al. Influence of common and specific HLA-DRB1/DQB1 haplotypes on genetic susceptibilities of three distinct Arab populations to Type 1 diabetes mellitus. *Clin Vaccine Immunol*. 2009;16(1):136–138. doi:10.1128/CVI.00215-08
- Hamzeh AR, Al Ali MT, Al-Khaja N, Al Ali MT. Association of HLA-DQA1 and -DQB1 alleles with type I diabetes in Arabs: a meta-analysis. *Tissue Antigens*. 2015;86(1):21–27. doi:10.1111/tan.12598
- Jahromi MM, Eisenbarth GS. Genetic Determinants of Type 1 Diabetes. Vol. 299. IntechOpen2006; 289–299.
- Zhang L, Gianani R, Nakayama M, Liu E, Kobayashi M. Type 1 diabetes: chronic progressive autoimmune disease. *Novartis Found Symp*. 2008;92:85–98.
- Nakanishi K, Inoko H. Combination of HLA-A24, -DQA1\*03, and -DR9 contributes to acute-onsetand early complete β-cell destruction in type 1 diabetes: Longitudinal study of residual β-cell function. *American Diabetes Association*. 2006;55(6):1862–1868. Available from: <https://diabetesjournals.org/diabetes/article/55/6/1862/15545/Combination-of-HLA-A24-DQA1-03-and-DR9-Contributes>. Accessed December 30, 2021.
- Pradana KA, Widjaya MA, Wahjudi M. Indonesians Human Leukocyte Antigen (HLA) distributions and correlations with global diseases. *Immunol Invest*. 2020;49(3):333–363. doi:10.1080/08820139.2019.1673771.
- Shojaeian A. An overview of the epidemiology of Type 1 diabetes mellitus. *Int J Metab Syndr*. 2020;2:1–5.
- Katsarou A, Gudbjörnsdottir S, Rawshani A, et al. Type 1 diabetes mellitus. *Nat Publ Gr*. 2017;3:1–18.
- Gregg B, Connor CG, Ruedy KJ, et al. Body mass index changes in youth in the first year after Type 1 diabetes diagnosis. *J Pediatr*. 2015;166(5):1265–1269.e1. doi:10.1016/j.jpeds.2015.02.036
- De Keukelaere M, Fieuws S, Reynaert N, et al. Evolution of body mass index in children with type 1 diabetes mellitus. *Eur J Ped*. 2018. 177(11):1661

### The Application of Clinical Genetics

Dovepress

#### Publish your work in this journal

The Application of Clinical Genetics is an international, peer-reviewed open access journal that welcomes laboratory and clinical findings in the field of human genetics. Specific topics include: Population genetics; Functional genetics; Natural history of genetic disease; Management of genetic disease; Mechanisms of genetic disease;

Counselling and ethical issues; Animal models; Pharmacogenetics; Prenatal diagnosis; Dysmorphology. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/the-application-of-clinical-genetics-journal>



# FESPA Global Print Expo

Connect With Leaders In Digital, Textile, Screen & Signage At Ar Global Reach.

FESPA Global Print Expo

## Application of Clinical Genetics

### COUNTRY

New Zealand



Universities and research institutions in New Zealand



Media Ranking in New Zealand

### SUBJECT AREA AND CATEGORY

Biochemistry, Genetics and Molecular Biology Genetics

Medicine Genetics (clinical)

### PUBLISHER

Dove Medical Press Ltd.

### H-INDEX

# 35

### PUBLICATION TYPE

Journals

### ISSN

1178704X

### COVERAGE

2008-2021


### INFORMATION

[Homepage](#)

[How to publish in this journal](#)


[editor-in-chief@dovepress.com](mailto:editor-in-chief@dovepress.com)





SCOPE




The Application of Clinical Genetics is an international, peer-reviewed, open access, online journal that welcomes laboratory and clinical findings in the field of human genetics. Original research, reviews, symposium reports, case studies, hypothesis formation and commentaries on the following: Population genetics Functional genetics Natural history of genetic disease Management of genetic disease Mechanisms of genetic disease Counseling and ethical issues Animal models Pharmacogenetics Prenatal diagnosis Dysmorphology As of 1st April 2019, The Application of Clinical Genetics will no longer consider meta-analyses for publication.

 Join the conversation about this journal

Psikolog Profesional Surabaya  
Psikolog Profesional Surabaya  
Berbagai Layanan Kesehatan Psikologi Tersedia Di Sini. Hubungi Kami untuk Detailnya.

Rute

Situs

 Quartiles  
  




Psikolog Profesional Surabaya

Psikolog Profesional Surabaya

Berbagai Layanan Kesehatan Psikologi Tersedia Di Sini. Hubungi Kami untuk Detailnya.


Rute

Situs


FIND SIMILAR JOURNALS ?

<p>1 <b>Molecular genetics &amp; genomic medicine</b> USA</p> <p><b>68%</b> similarity</p>	<p>2 <b>BMC Medical Genetics</b> GBR</p> <p><b>67%</b> similarity</p>	<p>3 <b>European Journal of Medical Genetics</b> FRA</p> <p><b>64%</b> similarity</p>	<p>4 <b>Clinical Gen</b> GBR</p> <p><b>6</b> s</p>
--	---	---	--

SJR




Total Documents




Total Cites

Self-Cites




Citations per document





External Cites per Doc

Cites per Doc




- Cites / Doc. (4 years)
- Cites / Doc. (3 years)
- Cites / Doc. (2 years)





Cited documents

Uncited documents



**Application of Clinical Genetics**

Q3 Genetics  
best quartile

SJR 2021  
0.51

powered by scimagojr.com


← Show this widget in your own website

Just copy the code below and paste within your html code:

```
<a href="https://www.scimaç
```

### SCImago Graphica

Explore, visually communicate and make sense of data with our **new data visualization tool.**



Metrics based on Scopus® data as of April 2022

**L** **Laura** 3 years ago

Dear Editorial Team,

What is the impact factor of the journal? Or, what was the impact factor in 2014, or if not available in 2014 or 2019, in any other year?

Thank you very much,

Claudia





**Melanie Ortiz** 3 years ago

Dear Laura, thank you very much for your comment. SCImago Journal and Country Rank uses Scopus data, our impact indicator is the SJR. We suggest you consult the Journal Citation Report for other indicators (like Impact Factor) with a Web of Science data source. Best Regards, SCImago Team

S **Sulman Basit** 3 years ago

What is the impact factor of the journal

reply



**Melanie Ortiz** 3 years ago

Dear Sulman, thank you very much for your comment. SCImago Journal and Country Rank uses Scopus data, our impact indicator is the SJR. The next SCImago's update will be made throughout this month (June 2020). We suggest you consult the Journal Citation Report for other indicators (like Impact Factor) with a Web of Science data source. Best Regards, SCImago Team

M **Mauricio Camargo, PhD** 3 years ago

About "The Application of Clinical Genetics" journal, ¿How many issues are published per year?

Thanks

reply

P **Prof. Dr. Martin H. Maurer** 3 years ago

Dear Dr. Camargo,

The journal is not organized in issues. All articles are published as soon as they are accepted and processed for publication. Please contact the journal home page at <https://www.dovepress.com/the-application-of-clinical-genetics-journal> or the Editorial staff for more information.

Best regards

Prof. Dr. Martin H. Maurer

Editor-in-Chief, The Application of Clinical Genetics



**Melanie Ortiz** 3 years ago

homepage or contact the journal's editorial staff , so they could inform you more deeply.  
Best Regards, SCImago Team

M **marjan** 3 years ago

what is the impact factor of this journal? I could not find it.

reply



**Melanie Ortiz** 3 years ago

SCImago Team

Dear Marjan, thank you very much for your comment.  
SCImago Journal and Country Rank uses Scopus data, our impact indicator is the SJR.  
Check out our web to localize the journal. We suggest you to consult the Journal Citation Report for other indicators (like Impact Factor) with a Web of Science data source. Best Regards, SCImago Team

Y **Younes kitane** 5 years ago

Hi , I need informations about the publishing prossess and the time table for publishing a case report about Dysferlinopathy .

Thanks

reply



**Elena Corera** 5 years ago

SCImago Team

Dear Younes, we suggest you locate the author's instructions on the journal's website.  
Best Regards, SCImago Team

#### Leave a comment

Name

Email

(will not be published)



I'm not a robot  
reCAPTCHA  
Privacy - Terms

Submit

The users of Scimago Journal & Country Rank have the possibility to dialogue through comments linked to a specific journal. The purpose is to have a forum in which general doubts about the processes of publication in the journal, experiences and other issues derived from the publication of papers are resolved. For topics on particular articles, maintain the dialogue through the usual channels with your editor.

Developed by:



Powered by:



Follow us on @ScimagoJR

Scimago Lab, Copyright 2007-2022. Data Source: Scopus®

EST MODUS IN REBUS

Horatio (Satire 1, 1, 106)

[Cookie settings](#)

[Cookie policy](#)

